About Us
CellMosaic® Inc. is a Leader in Innovative Bioconjugation and Drug Delivery Solutions
CellMosaic® is a Massachusetts-based technology company deliverying high-quality and innovative bioconjugation solutions powered by proprietary AqueaTether® (AqT®) Technologies and Advanced Conjugation Processes.
Bioconjugates are widely used as research tools, diagnostic reagents, and as an emerging therapeutic modality, including antibody–drug conjugates (ADCs). Due to the inherent complexity of bioconjugation and the multidisciplinary expertise required across chemistry, biology, and manufacturing, few companies are able to consistently deliver high-quality bioconjugation services and products. Founded in 2008 by Dr. Huang, CellMosaic was established to address this gap, leveraging her extensive experience in bioconjugation, drug development, and manufacturing.
Since its inception, CellMosaic has invested significantly in the development of Advanced Conjugation Processes and has developed 400+ proprietary processes supported by validated manufacturing protocols and comprehensive QC systems. Building on this foundation, CellMosaic has established a successful custom conjugation services business, delivering 700+ custom projects and 500+ unique custom conjugates across diverse research and development fields (as of February 2026).
In late 2016, CellMosaic began commercializing its personalized conjugation kits (PerKit®). By December 2017, the PerKit product line expanded to include antibody drug conjugate (ADC) and protein drug conjugate (PDC) kits, enabling customers to prepare high-quality conjugates in-house comparable to those produced at CellMosaic. Frequently used chemicals and conjugates are also offered as reagent products. As of February 2026, PerKit® and reagent products have been sold to 450+ organizations across 33+ countries worldwide.
In 2011, CellMosaic initiated the development of a new class of linkers designed to address the challenges associated with labeling and conjugating hydrophobic compounds. The company pioneered the use of natural, edible sugar alcohols to create novel link and polymer carrier systems known as AqueaTether (AqT) technologies for conjugation and drug delivery. This platform was supported in part by competitively awarded funding from the U.S. Department of Defense Breast Cancer Research Program (BCRP) Breakthrough Award (2015-2018) and continues to advance through CellMosaic’s internal R&D efforts.
Based on AqT technology, CellMosaic has commercialized next-generation bioconjugation kits and products. The AqT platform also enables the development of enhanced therapeutics across a broad range of drug modalities and indications, accelerating drug discovery and supporting the development of optimized drug candidates.
Over the years, CellMosaic has developed additional proprietary technologies, including oxLink™ and sxLink™ for studying protein–protein interactions (supported by NIH SBIR funding) and NeIon™ for detecting and quantifying trace analytes by mass spectrometry. Selected products based on these technologies are available for research usage.
CellMosaic currently organizes its operations into four business units to meet customer demand for high-quality, innovative, and advanced bioconjugation solutions:
- Reagents/Kits: Pre-made bioconjugates, labeled or modified molecules, and kits that enable customers to prepare bioconjugates in-house.
- R&D Bioconjugation Services: Custom Bioconjugation Services and standardized bioconjugation under our Routine Synthesis™ platform.
- Contract Development and Manufacturing (CDMO): Process development, scale-up, and GLP/GMP manufacturing of bioconjugate drugs and diagnostic conjugates, including the ADC development using clinically validated classical linkers.
- AqT® ADC Development and Manufacturing: Enabling customers to leverage innovative AqT® linkers for next-generation ADC development and manufacturing.